This trial will test whether nabilone, a synthetic marijuana derivative, is better than placebo at relieving itch in people undergoing hemodialysis.
- Kidney Failure
1 Primary · 4 Secondary · Reporting Duration: Measured at study baseline and weeks 1,2,3,4,5,6,7,8,9,10,11
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
12 Total Participants · 2 Treatment Groups
Primary Treatment: Nabilone 0.5 MG Oral Capsule · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the research history of Nabilone 0.5 MG Oral Capsule?
"Researchers are currently conducting 6 trials on Nabilone 0.5 MG Oral Capsule, 3 of which have reached Phase 3 testing. Most of the work is being done in Toronto, but there are 9 other locations where Nabilone 0.5 MG Oral Capsule studies are taking place." - Anonymous Online Contributor
Are new participants currently being signed up for this experiment?
"Unfortunately, this study is not taking any more patients at the moment. The clinicaltrials.gov website reports that the last date for recruitment was May 16th, 2022. There are, however, 639 other trials currently looking for participants." - Anonymous Online Contributor
How many individuals are receiving treatment as part of this research project?
"This particular trial is no longer enrolling patients. The listing for the study was first posted on June 1st, 2022 and updated for the last time on May 16th, 2022. There are other trials with similar parameters that are currently looking for participants; 633 clinical trials for pruritus and 6 for Nabilone 0.5 MG Oral Capsule." - Anonymous Online Contributor
Do people often experience negative side effects from taking Nabilone 0.5 MG Oral Capsule?
"There is some evidence to support the efficacy of Nabilone 0.5 MG Oral Capsule, as it has progressed to Phase 3 in clinical trials. Furthermore, multiple rounds of data have been collected supporting its safety, so it receives a score of 3 from our team at Power." - Anonymous Online Contributor